To,

31.03.2020

The Manager-Listing
NSE Limited
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2020 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

For MICRO LABS LIMITED

For MICRO LABS LIMITED

Company Secretary

Authorised Signatory

Copy to:
Compliance Officer
BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA MICRO LABS LIMITED		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	13,10,836	9.25%	9.25%
TOTAL	13,10,836	9.25%	9.25%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

For MICRO LABS LIMITED

Place: Bangalore
Date: 31.03.2020

Company Secretary

Authorised Signatory

To,
The BSE Limited
Mumbai.

31.03.2020

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on our shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

For Micro Labs Limited

Company Secretary

C.C to The Chairman, Audit Committee

To,

31.03.2020

The Manager-Listing
NSE
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2020 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

DILIP SURANA

Copy to:
Compliance Officer
BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA DILIP SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	4,74,994	3.35%	3.35%
TOTAL	4,74,994	3.35%	3.35%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:
1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2020

DILIP SURANA

To,
The BSE Limited
Mumbai.

31.03.2020

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Dilip Surana

C.C to The Chairman, Audit Committee

To,

31.03.2020

The Manager-Listing
NSE Limited
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2020 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

DILIP SURANA (HUF)

Copy to:
Compliance Officer
BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA DILIP SURANA (HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	1,69,995	1.20%	1.20%
TOTAL	1,69,995	1.20%	1.20%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2020

DILIP SURANA (HUF)

To,
The BSE Limited
Mumbai.

31.03.2020

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Dilip Surana (HUF)

C.C to The Chairman, Audit Committee

To,

31.03.2020

The Manager-Listing
NSE
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2020 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

ARCHANA SURANA

Copy to:
Compliance Officer
BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA ARCHANA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	2,84,996	2.01%	2.01%
TOTAL	2,84,996	2.01%	2.01%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2020

ARCHANA SURANA

To,
The BSE Limited
Mumbai.

31.03.2020

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Archana Surana

C.C to The Chairman, Audit Committee

To,

31.03.2020

The Manager-Listing
NSE
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI, I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2020 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

ANAND SURANA

Copy to:
Compliance Officer
BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA ANAND SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares.	% w.r.t.total share /voting capital wherever applicable.	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	5,25,686	3.71%	3.71%
TOTAL	5,25,686	3.71%	3.71%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2020

ANAND SURANA

To,
The BSE Limited **31.03.2020**
Mumbai.

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Anand Surana

C.C to The Chairman, Audit Committee

To,

31.03.2020

The Manager-Listing
NSE
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2020 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

Monica

MONICA SURANA

Copy to:
Compliance Officer
BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (inclding that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA MONICA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	1,79,909	1.27%	1.27%
TOTAL	1,79,909	1.27%	1.27%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2020

MONICA SURANA

To,
The BSE Limited
Mumbai.

31.03.2020

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Monika Surana

C.C to The Chairman, Audit Committee

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA SUBBA RAO PRASANNA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t.total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	20,200	0.14%	0.14%
TOTAL	20,200	0.14%	0.14%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1.In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Prasanna

Date: 31.03.2020

SUBBA RAO PRASANNA

To,
The BSE Limited

31.03.2020

Mumbai.

NSE Limited
Mumbai.

Dear Sir,

Ref : Declaration as per Regulation 31(4) of SEBI (SAST) Regulations,2011.

With reference to the above, I would like to confirm that I has not made any encumbrance on my shareholding in Bal Pharma Limited either directly or indirectly, during the financial year ended 31.03.2020.

Please take this intimation on record.

Thanking You.

Subba Rao Prasanna

C.C to The Chairman, Audit Committee